ATP13A2 (also called PARK9), is a transmembrane endo-/lysosomal-associated P5 type transport ATPase. Loss-of-function mutations in ATP13A2 result in the Kufor-Rakeb Syndrome (KRS), a form of autosomal Parkinson's disease (PD). In spite of a growing interest in ATP13A2, very little is known about its physiological role in stressed cells. Recent studies suggest that the N-terminal domain of ATP13A2 may hold key regulatory functions, but their nature remains incompletely understood. To this end, we generated a set of melanoma and neuroblastoma cell lines stably overexpressing wild-type (WT), catalytically inactive (D508N) and N-terminal mutants, or shRNA against ATP13A2. We found that under proteotoxic stress conditions, evoked by the proteasome inhibitor Bortezomib, endo-/lysosomal associated full-length ATP13A2 WT, catalytically-inactive or N-terminal fragment mutants, reduced the intracellular accumulation of ubiquitin-conjugated (Ub) proteins, independent of autophagic degradation. In contrast, ATP13A2 silencing increased the intracellular accumulation of Ub-proteins, a pattern also observed in patient-derived fibroblasts harbouring ATP13A2 loss-of function mutations. In treated cells, ATP13A2 evoked endocytic vesicle relocation and increased cargo export through nanovesicles. Expression of an ATP13A2 mutant abrogating PI(3,5)P2 binding or chemical inhibition of the PI(3,5)P2-generating enzyme PIKfyve, compromised vesicular trafficking/nanovesicles export and rescued intracellular accumulation of Ub-proteins in response to proteasomal inhibition. Hence, our study unravels a novel activity-independent scaffolding role of ATP13A2 in trafficking/export of intracellular cargo in response to proteotoxic stress. † Present address:
Introduction
Regulated turnover, trafficking and export of intracellular proteins maintains the quality of the proteome (proteostasis), which is required for proper cell function. To maintain proteostasis and prevent proteotoxicity, as a result of the accumulation of aged or aberrantly folded proteins, cells are dependent on two key proteolytic/trafficking systems; the proteasome and the endo-/lysosomal network (1) . The relevance of these quality control mechanisms for cellular proteostasis is supported by increasing evidence implicating impairments in endo-/lysosomal degradation and sorting pathways in a variety of diseases, including neurodegenerative disorders, like Parkinson's disease (PD) (2, 3) , and cancer (2, (4) (5) (6) . A better understanding of the mechanisms controlling protein degradation and sorting may offer new therapeutic perspectives and strategies.
ATP13A2, (also called PARK9, CLN12 or SPG78 (7), OMIM 610513), encodes for a ubiquitously expressed endo-/lysosomalassociated P5-type transport ATPase, with an emerging biological function in the regulation of cellular proteostasis. Several pathogenic mutations in ATP13A2 have been implicated in Kufor-Rakeb Syndrome (KRS, OMIM 606693), a form of autosomal recessive Parkinsonism associated with dementia (8, 9) , and hereditary spastic paraplegia, a group of heterogeneous neurodegenerative disorders characterized by progressive spasticity of the lower limbs due to axonopathy of the corticospinal neurons (7) . All the so far-characterized ATP13A2 mutations result in a depletion of the protein from the endo-/lysosomal network, which is likely caused by a retention or mislocalization of these ATP13A2 mutants to the ER, followed by their rapid degradation through the ERAD pathway. The rapid degradation of these ATP13A2 mutant proteins compared to the wild-type (WT), suggests a link between the loss-of-function of ATP13A2 in the endo-/lysosomal system with the cellular pathology of KRS. All together, these studies suggest that loss-of-function of ATP13A2, resulting in its depletion from the endo-/lysosomal network, is detrimental for proteostasis and triggers a pathogenic mechanism that underlies a spectrum of neurological disorders.
Very little is known about the physiological role of ATP13A2. Although ATP13A2 undergoes autophosphorylation at the D508 residue, a typical feature of P-type transporters, its transported substrate remains unknown (10) . ATP13A2 displays a remarkable topology comprising a membrane-embedded core for substrate binding/transport and a peculiar N-terminus that interacts with the cytosolic membrane leaflet of the endo-/ lysosomal compartment (10) . ATP13A2 may regulate the homeostasis of the endo-/lysosomal network through different mechanisms. Indeed, based on the expression of ATP13A2 mutants or silencing strategies, recent studies have implicated ATP13A2 in preserving lysosomal function and autophagosome turnover (11) , regulating the biogenesis and secretion of exosomes (12, 13) , and in protecting cells against divalent metal ions (14-16) and a-synuclein toxicities (11, 17, 18) .
Interestingly, we recently found that the ATP13A2 N-terminus is a key regulatory domain interacting with two endo-/lysosomal signaling lipids, phosphatidic acid (PA) and phosphatidylinositol (3, 5) bisphosphate (PI(3,5)P2) (10) , which unlock ATP13A2 catalytic activity to provide cellular protection against mitochondrial stress and metal toxicity (19) . However, the molecular mechanisms by which ATP13A2 exerts these diverse biological functions remain unclear. Given the high number of identified or proposed protein interactors (20) , ATP13A2 may exert both transport dependent and transport independent/scaffolding functions, which is often seen for other P-type ATPases (21) . Thus, it remains to be further established whether all the ATP13A2-mediated endo-/lysosomal effects require the catalytic activity of ATP13A2 or depend on the regulation by N-terminal PA and PI(3,5)P2 interaction, both under basal and cellular stress conditions. Moreover, despite the impact of ATP13A2 on a-synuclein toxicity and lysosomal degradation capacity, no studies so far have addressed the role of ATP13A2 under conditions of loss of proteostasis, as induced e.g. by proteasomal inhibition, when cells must rely more heavily on the endo-/lysosomal network to avoid proteotoxicity.
In this study, we aimed to further delineate the putative role of ATP13A2 in the regulation of proteostasis. We show that upon inhibition of the proteasome, ATP13A2 regulates crucial steps of cargo trafficking and sorting processes in the endocytic system. This function of ATP13A2 is elicited through a previously unrecognized scaffolding role of its cytosolic N terminal domain, independent of its catalytic activity. Finally, we show that this N terminal domain-driven function of ATP13A2 requires the interaction with the signalling lipid PI(3,5)P 2 to potentiate the release of cytoplasmic cargo through export via nanovesicles.
Results

A scaffolding function of ATP13A2 facilitates ubiquitin-conjugated proteins turnover in cells responding to inhibition of the proteasome
To gain more mechanistic insights into the non-pathogenic role of ATP13A2 in protein homeostasis, we chose the human melanoma A375p and the neuroblastoma SHSY5Y cell lines, for several reasons. Besides being of similar neuronal crest origin: i) melanoma cells are an emerging paradigm of cancer cells harnessing the endo-/lysosomal system to support oncogenedriven growth (5), thus providing an ideal cellular model to explore molecular mechanisms linked to proteostasis regulation and proteotoxicity; ii) the role of ATP13A2 in melanoma cell's proteostasis has never been explored and iii) the SHSY5Y neuroblastoma cell line is largely used as a model to investigate the molecular basis of PD-associated genes, including ATP13A2 (22) .
We then generated a set of cell lines stably expressing comparable expression levels of WT or a catalytically inactive variant of ATP13A2 with a defective autophosphorylation (D508N) (10) (Supplementary Material, Fig. S1A and B) , a flag-tagged truncated protein corresponding to the N-terminal lipid-binding regulatory domain of ATP13A2 (N-ter) (10) (Supplementary Material, Fig. S1A and B) , and a shRNA against ATP13A2 (sh-ATP13A2) (Supplementary Material, Fig. S1C and D) . Of note, in our hand, the endogenous level of ATP13A2 in these cell lines was below immunodetection using different, currently available (possibly low affinity) ATP13A2 antibodies. Cell lines expressing a firefly-luciferase (Fluc) or a miRNA based short-hairpin sequence against firefly luciferase (mirFluc), which behaved similarly, were used as interchangeable controls.
In line with previous reports from ourselves (10, 19) and others (8, 13, 23) , we found that ATP13A2 is associated to the endo-/lysosomal compartment. In both A375p and SHSY5Y cell lines the ATP13A2 variants co-localized with the lysosomal markers LAMP1 and LAMP2 and the late endosomal/intraluminal vesicle marker CD63 (Supplementary Material, Fig. S1E and F), while the expression of N-ter showed a more predominant co-localization with CD63-decorated vesicles (Supplementary Material, Fig. S1E and F Fig. S1H and I) . Likewise, manipulations of ATP13A2 expression levels in the A375p cells did not significantly alter the overall degradative capacity -as measured by DQ-BSA which, following endocytosis, undergoes dequenching upon proteolysis (Supplementary Material, Fig. S1J )-and overall LAMP1/LAMP2 fluorescence intensity (Supplementary Material, Fig. S1K and L) . Moreover, manipulation of ATP13A2 expression did not affect the basal autophagic flux of both A375p and SHSY5Y cell lines (as assessed in Fig. 2A-E) .
Altogether, these observations show that manipulations of the ATP13A2 expression levels do not cause gross disturbances in the homeostasis of the endo-/lysosomal network under baseline conditions, consistent with results reported in SHSY5Y cells, where ATP13A2 deficiency did not alter general lysosomal/degradative functions under basal conditions (24) .
Next, to decipher the function of ATP13A2 in protein quality control, we subjected A375p and SHSY5Y cell lines to Bortezomib (Borte), a selective inhibitor of the proteasome, one of the major protein quality control mechanisms. This stress condition typically manifests in the intracellular accumulation of ubiquitin-conjugates of proteins (Ub-proteins), which tend to form Ub-proteins aggregates that can ultimately cause proteotoxicity (25) . To this end, we first analysed the pattern of Ubproteins accumulating in our cellular systems in response to Borte by immunoblotting with an anti-Ub antibody. Kinetic studies showed that accumulation of Ub-proteins after Borte reached a peak after 16-24 h (data not shown), hence we chose 24h treatment as most representative endpoint for further comparison across cell lines. Furthermore, to image the formation of Ub-conjugates after treatment, we also used confocal microscopy in cells transiently transfected with GFP-tagged ubiquitin (GFP-Ub).
Both immunoblotting (Fig. 1A and B) and fluorescence analysis of GFP-Ub expressing cells (Fig. 1C) , showed that while in untreated SHSY5Y or A375p cells the baseline pattern of Ubproteins was unaltered, in response to Borte treatment the overexpression of WT ATP13A2 in these cells alleviated the intracellular accumulation of Ub-proteins ( Fig. 1A and B) and reduced GFP-Ub granularity (Fig. 1C) . On the other hand, after treatment the ATP13A2-silenced cells exhibited, compared to the control cells, a slight but significant increase in the accumulation of Ub-tagged proteins, as detected by western blotting (Fig. 1A) , and of large GFP-Ub puncta (Fig. 1C) . Strikingly, the reduced Ub-accumulation observed in the treated WT ATP13A2 cells, was phenocopied by the D508N and N-ter overexpressing cells (Fig. 1A and C) . These findings were further confirmed by cell fractionation analysis, whereupon the pattern of Ubproteins in the insoluble aggregate fractions of the treated cells echoed the pattern found in the cytoplasmic fractions (Fig. 1D) , reflecting a reduced or increased amount of insoluble Ubproteins in ATP13A2 WT or shRNA-ATP13A2 transduced cells, respectively (Fig. 1D) .
Similar results were obtained with another proteasomal inhibitor MG132 (Supplementary Material, Fig. S2A ), but not when the cells were exposed to endo-/lysosomal alkalinizing agents, such as Bafilomycin A1 (BafA1) (Supplementary Material, Fig.  S2B ), which did not elicit major changes in the intracellular Ubpattern. Also Borte did not affect the protein levels of various endo-/lysosomal markers (Supplementary Material, Fig. S2C and D), further ruling out that changes in Ub-proteins turnover observed may be due to a general impairment of the endo-/ lysosomal network. Moreover, blockage of caspase 3 by the pancaspase inhibitor z-VAD-FMK 24h after Borte treatment did not affect the pattern of Ub-proteins turnover exhibited by these cells, suggesting that the effects of ATP13A2 expression on the Ub-associated phenotype cannot be attributed to activation of apoptotic caspase signalling in response to proteotoxic stress (Supplementary Material, Fig. S2E ).
Predicted loss-of function mutations in ATP13A2, such as the hereditary spastic paraplegia (HSP) ATP13A2 p.T512I point mutation (7, 10) or the Kufor-Rakeb truncating p.Phe851Cysfs*6 mutation (p.F851CfsX856), causing a premature stop codon (7), have been shown in different cellular models to elicit retention of ATP13A2 in the ER, and its exclusion from the endo-/ lysosomal system (7, 9, 10) . We then tested if these diseaseassociated, loss-of-function ATP13A2 mutants, could evoke an Ub-proteins phenotype reminiscent to that observed in the ATP13A2-silenced A375p and SHSY5Y cells upon treatment with Bortezomib.
Importantly, treatment of fibroblasts derived from patients harbouring either the HSP-or Kufor-Rakeb ATP13A2 mutations with Borte resulted in a remarkable accumulation of Ubproteins, at a time point (48h) after which healthy fibroblasts did not display an observable accumulation of Ub-proteins yet (Fig. 1E) . However, while prolonging Borte treatment (96 h) resulted in a measurable increase of Ub-proteins also in fibroblasts from healthy donors as compared to their untreated controls, patient-derived fibroblasts harbouring ATP13A2 loss-of function mutation still showed a heightened accumulation of Ub-proteins, when compared to the treated healthy cells (Supplementary Material, Fig. S2F ). These observations further reinforce the crucial biological role of ATP13A2 in the maintenance of cellular proteostasis.
Altogether, these results indicate that upon inhibition of the proteasome, ATP13A2 promotes the turnover of ubiquitinated proteins, through a mechanism independent of its catalytic activity but entailing its N-terminal domain.
ATP13A2 promotes ubiquitin-protein turnover mainly through autophagy independent mechanisms
Recent studies reported that ATP13A2 is a regulator of macroautophagy (26,27) (here simply called autophagy). Since autophagy is a key pathway maintaining the integrity of the proteome (28), we hypothesized that ATP13A2 regulates proteostasis by modulating Ub-proteins clearance through the autophagosomes.
To test this hypothesis, we first monitored autophagy in untreated and Borte-treated cells, by measuring the conversion of LC3-I to the lipidated, autophagosome-associated LC3-II by western blotting. While in untreated conditions we could not detect differences across cell lines, Borte treatment led to a time-dependent measurable increase in LC3-II formation ( Fig. 2A) , which was particularly significant in cells expressing the ATP13A2 WT and the D508N mutant ( Fig. 2A) . In contrast, in cells expressing the N-terminal fragment or transduced with the sh-ATP13A2, LC3-II levels after Borte treatment were comparable to that of control cells, at least within the linear range of exposure of the blot ( Fig.2A) . Likewise, imaging analysis in cells expressing GFP-LC3 and treated for 6 h with Borte (an early time point chosen to avoid major morphological changes due to cell death induction), showed that only cell lines overexpressing WT or the D508N mutant of ATP13A2 displayed an increase in GFP-LC3 puncta in response to proteasomal inhibition. Again, in ATP13A2-silenced cells or cells expressing the N-ter, the amount of GFP-LC3 puncta after 6h treatment was only poorly increased as compared to the untreated cells (Fig. 2B ). These results were further confirmed by immunoblotting in both A375p ( Fig. 2C ) and SHSY5Y ( Fig. 2D ) cell lines.
Although these data suggest modulation of autophagy by ATP13A2 under conditions of proteotoxic stress, an increased level of LC3-II or GFP-LC3 granularity may result from an increased formation of autophagosomes or decreased autophagosomal degradation/clearance. We then assessed autophagic flux in our cellular models, by transfecting the cells with the tandem mRFP-GFP-LC3 construct and imaging puncta formation in untreated and treated conditions. In this assay, loss of GFP-LC3 fluorescence occurring in the acidic environment of the autolysosome-and increased RFP-LC3 signal indicates functional autophagy (i.e. autophagic flux). Upon proteasome inhibition, mRFP-GFP-LC3 transfected control, ATP13A2-silenced cells and cells expressing the ATP13A2 N-terminal fragment, exhibited an accumulation of red fluorescent vesicles (autolysosomes) indicating an intact autophagic flux capacity (Fig. 2E ). In contrast, cells expressing ATP13A2 WT or its catalytic inactive mutant D508N, displayed an enhanced amount of uncleared autophagosomes, identified as yellow fluorescent vesicles (Fig. 2E) . As a positive control, mRFP-GFP-LC3 expressing cells were also cotreated with the autophagic flux blocker BafA1. Co-treatment of Borte with BafA1 led to an accumulation of yellow fluorescent vesicles in the ATP13A2-silenced cells and N-terminal fragment expressing cells, while it failed to further increase their presence in the ATP13A2 WT and D508N-mutant cells (Fig. 2E) , thus confirming the inability to perform functional autophagy exhibited by the latter cells upon treatment.
To further confirm this analysis, we quantified LC3-II formation by immunoblotting in the absence or presence of BafA1. In this case, the further accumulation of LC3-II in the presence of BafA1 is a reflection of the ON-status of autophagy. In analogy with the mRFP-GFP-LC3 data, addition of BafA1 did not cause an increase in LC3-II in the ATP13A2 WT and D508N-mutant cells after Borte treatment, while LC3-II accumulated further in the ATP13A2-silenced cells and cells expressing the N-terminal fragment (Supplementary Material, Fig. S3A ). Also, addition of BafA1 did not alter the pattern of Ub-proteins displayed by the WT and D508N-mutant expressing cells (Supplementary Material, Fig.  S3B ), further suggesting that cargo degradation through autophagy, is unlikely to be the major mechanism contributing to the observed increased turnover of Ub-proteins displayed by these cells.
In support of this hypothesis, while no difference across cell lines was observed in the DQ-BSA assay in untreated conditions (Supplementary Material, Fig. S1J ), the overall degradative capacity of the control cells and ATP13A2-silenced cells upon Borte-treatment was increased or remained unaltered in the case of the cells expressing N-ter (Fig. 2F) . In contrast, the proteolytic capacity of ATP13A2 WT or D508N-mutant expressing cells dropped significantly after treatment (Fig. 2F) , further revealing the compromised degradative capacity of these cells.
Together, these results suggest that autophagic degradation is not the main pathway controlling ubiquitin turnover in cells expressing ATP13A2, upon proteasomal inhibition.
ATP13A2 enhances the trafficking and export of cargo through nanovesicles
The findings that Borte-treated cells expressing either WT and D508N-mutant ATP13A2 display a reduced Ub-proteins accumulation combined with reduced degradative capacity, while ATP13A2-silenced cells show intact autophagic degradation along with increased Ub-proteins accumulation, were difficult to reconcile. We then speculated that these ATP13A2-evoked phenotypes could reflect perturbations in mechanisms regulating trafficking and/or extracellular export of intracellular materials in response to the loss of proteostasis. This hypothesis was also supported by recent findings linking ATP13A2 with trafficking through multivesicular bodies (MVBs) and increased secretion of alpha-synuclein (12, 13) .
Although ATP13A2 had no effect on the expression of components of the endo-/lysosomal machinery (Supplementary Materials, Figs. S1H and I, S2C and D), we analysed whether ATP13A2 could modulate the redistribution of endocytic vesicles within the cells. In order to capture early changes in vesicular trafficking prior to manifestations of proteotoxic stress, we chose an early time point after treatment.
Following 8 h of Borte exposure, A375p ( Fig. 3A and B) cell lines expressing WT, D508N-mutant and N-ter showed a significant redistribution of LAMP1þ vesicles from the perinuclear region towards the periphery of the cell (Fig. 3A and quantified in 3B). In contrast, Borte-treatment did not elicit peripheral LAMP1þ redistribution in the shATP13A2-expressing and control cells (Fig. 3A and B) . Moreover, co-staining of ATP13A2 with CD63 and LAMP1 showed that while in untreated WT overexpressing cells, ATP13A2 co-localized with mainly perinucleardistributed CD63þ/LAMP1þ vesicles, after Borte-treatment ATP13A2 redistributed along with the peripheral pool of CD63þ/ LAMP1þ vesicles in A375p (Fig. 3C ) and LAMP1þ vesicles in SHSY5Y (Fig. 3D) .
During endosomal sorting, Ub-proteins are recognized on the endosomal membrane and fated to be either degraded by the lysosomes, or released extracellularly via nanovesicles (29) . Given the redistribution phenotype ( Fig. 3A and D) and the reduced degradative capacity of the cells expressing ATP13A2 WT, D508N-and N-terminal mutants compared to control cells after Borte-treatment (Fig. 2F) , we reasoned that upon the loss of proteostasis ATP13A2 may favour the export of Ub-cargo proteins via nanovesicles.
To this end, we purified crude nanovesicles fractions from untreated and treated A375 cells and measured their protein content amount, as a readout for their endo-/lysosomal export capacity. Notably, while untreated cells did not show gross differences, following Borte exposure, the overall amount of proteins carried by the nanovesicles was significantly higher in the WT, DN and N-ter cell lines (Fig. 4A) . The released nanovesicle fractions were positive for key exosomal markers TSG101 and CD9, thus validating the isolation of the nanovesicles in this fraction (Fig. 4B) . It should be noted that, although the overall amount of proteins carried by the nanovesicles is similar after treatment of controls and sh-ATP13A2-transduced melanoma cells, we cannot exclude that endogenous levels of ATP13A2 affects nanovesicle size, number and composition.
Although our results highlight a clear correlation between the intracellular pattern of Ub-proteins, relocation of CD63þ/ LAMP1þ vesicles and exodus of nanovesicles in an ATP13A2-modulated fashion, we were unable to detect the presence of Ub-conjugated proteins in the secreted nanovesicles by immunoblotting (data not shown). Recent studies (30, 31) reported that Ub-proteins cargo may be deubiquitinated either before or after sorting and/or being incorporated into the LEs/MVBs, especially under conditions of proteotoxic stress (30) . Interestingly, we found that both the levels of intracellular Ub-proteins and of the crude nanovesicular fractions were sensitive to the presence of the pan-deubiquitinating enzyme inhibitor PR619. In Borte-treated WT and D508N ATP13A2 cells, presence of PR619 increased the intracellular Ub-proteins accumulation, albeit not to control levels (Supplementary Material, Fig. S4A ), while it concomitantly reduced the capability of these cells to export nanovesicles (Supplementary Material, Fig. S4B ). While these data support a causal link between enhanced intracellular Ubprotein clearance and export mechanisms, they also suggest that prior to ATP13A2-mediated cargo sorting and export, protein cargo requires deubiquitination.
Thus upon proteasomal inhibition, ATP13A2 increases vesicular trafficking and cargo export of ubiquitinated proteins through mechanisms independent of its catalytic activity.
ATP13A2 increases the endocytic export of cargo in a PI(3,5)P2-dependent manner
Our results reveal that trafficking and export mechanisms elicited by ATP13A2 are modulated primarily by the scaffolding role of its N-terminus. Interestingly, our recent study uncovered that the unique N-terminal domain of ATP13A2 is modulated by phosphatidic acid (PA) and phosphatidylinositol (3,5) bisphosphate (PI(3,5)P2), two stress inducible, signalling lipids involved in the regulation of the endo-/lysosomal network (10) . Therefore, we decided to investigate the regulatory role of these lipids in our settings.
To this end, we monitored the intracellular Ub-phenotype when the formation of PI(3,5)P2 and PA was prevented, i.e. upon pretreatment with respectively YM-201636 (a PIKfyve kinase inhibitor) ( Fig. 5A and B) or FIPI (a phospholipase D, PLD inhibitor) (Supplementary Material, Fig. S5A ). Notably, while these inhibitors alone ( Fig. 5A and B, Supplementary Material, Fig. S5A ) had no influence on intracellular Ub-proteins turnover, inhibition of PI(3,5)P2 formation in the Borte treated cells consistently inhibited the increased Ub-proteins turnover of WT, D508N-and N-terminal expressing cells, yet had no significant effect on the shATP13A2-transduced cell lines (Fig. 5A and B). Interestingly, FIPI had no significant effect on ATP13A2-mediated turnover of Ub-proteins (Supplementary Material, Fig. S5A ), suggesting a specific effect elicited by PI(3,5)P2.
To further confirm that lipid interaction on the N-terminus modulates ATP13A2 scaffolding function, we turned to stable cell lines overexpressing full length ATP13A2 harbouring mutations in the critical N-terminal lipid binding sites (LBS123) (10, 19) . In line with the data obtained by pharmacological inhibition, blocking ATP13A2's capacity to interact with signalling lipid PI(3,5)P2 by mutagenesis, reduced its ability to mediate increased Ub-proteins turnover (Fig. 5C and D) .
We then analysed whether prevention of the PI(3,5)P2 binding to the ATP13A2 N-terminus would affect vesicular trafficking and export mediated by ATP13A2 after Borte treatment. Remarkably, LBS123 expressing cells failed to re-localize the pool of ATP13A2-associated CD63þ/LAMP1þ vesicles towards the cell periphery (Supplementary Material, Fig. S5B ). Furthermore, both pre-treatment with the PIKfyve inhibitor and the expression of the ATP13A2 LBS123 mutant, prevented the increased release of nanovesicles observed in the ATP13A2 WT cell lines after treatment (Fig. 5E and F ).
In conclusion, these findings suggest that in cells undergoing proteotoxic stress, PI(3,5)P2 binding to the N-terminal domain of ATP13A2 stimulates relocalization of CD63þ/LAMP1þ vesicles near the plasma membrane and extracellular export of intracellular cargo via nanovesicles. 
Discussion
Our study highlights a novel biological role for the P-type ATPase ATP13A2 as an endo-/lysosomal scaffold protein mediating trafficking and export of protein cargo in response to loss of proteostasis. We found that ATP13A2 regulates proteostasis independent of transport activity, by binding of the endocytic signalling lipid PI(3,5)P2 to the ATP13A2 N-terminus leading to the remodelling of the endocytic pathway towards a predominant vesicular export phenotype. In this study, besides the widely used dopaminergic neuroblastoma SHY5HY cells, we used as a primary cellular model system, the metastatic A375p melanoma cells known to rely on a heightened endo-/lysosomal system to dynamically model their proteome and support their aggressive behaviour (5) . Exploring the role of ATP13A2 in these cellular models was interesting also considering that failure to maintain proteostasis and vulnerability to proteotoxic stress, are phenomena associated to both cancer and neurodegeneration (32, 33) . Moreover, an unexplained epidemiological association exists between melanoma and PD (34) (35) (36) , which is further supported at the genetic level by recent evidence linking PARKIN/PARK2 mutations to PD and melanoma (37) . Whether this is related to shared pathways and the common neural crest origin of dopaminergic neurons and melanocytes, is not completely known but remains an attractive hypothesis. Furthermore, we confirmed salient features of the unprecedented role of ATP13A2 in proteostasis uncovered in this study, in patient-derived fibroblasts harbouring ATP13A2 loss-of function mutations (7, 9, 10) .
Our results show that, upon inhibition of the proteasome, SHSY5Y and A375 cells accumulate less Ub-proteins when either WT ATP13A2 or the catalytically inactive D508N-mutant is expressed. Strikingly, we found that the N-terminal domain of ATP13A2 was sufficient to phenocopy and incite the enhanced Ub-proteins turnover phenotype observed after proteotoxic stress. These results thus reveal a scaffolding role of ATP13A2 executed through its N-terminal domain, which enables a faster turnover of intracellular Ub-proteins, accumulating after proteasomal inhibition. This is an interesting finding, as so far no other study has highlighted a role for ATP13A2 independent of its putative transport function. Also other P-type transport ATPases, such as the Na þ /K þ -ATPase, exert pump-independent functions as scaffolds (38) or even receptors (39) .
Most disease mutations associated with KRS or HSP are unstable and are retained in the ER prior to degradation by ERAD (7, 9, 40) . Our data show that when cells experience loss of proteostasis, loss-of function of ATP13A2 perturbs protein quality control mechanisms, as evidenced by the intracellular accumulation of Ub-proteins in ATP13A2-silenced melanoma and neuroblastoma cell lines as well as in patient-derived fibroblasts harbouring loss-of function mutations in ATP13A2. This suggests that loss of the ATP13A2 scaffolding functions is deleterious for the proper management of the proteome under stress, thus revealing a novel and broad function of ATP13A2.
While this study focussed mainly on uncovering the main biological function of ATP13A2 in the maintenance of the proteome integrity, it will be important to study in the future whether other transport-deficient ATP13A2 mutants might escape the ER and reach the endo-/lysosomal compartment leaving the scaffolding function of ATP13A2 intact. In fact it remains unclear whether such mutations are pathogenic or cause a different phenotype, which might explain why ATP13A2 is implicated in several neurological disorders including KRS (40, 41) , neuronal ceroid lipofuscinosis (42) and hereditary spastic paraplegia (7). However, unstable ATP13A2 truncation mutants can be found both in KRS and HSP patients, indicating that the combined loss of the scaffolding and transport functionalities of ATP13A2, could contribute to endo-/lysosomal defects in several ATP13A2-dependent diseases.
Recent studies in dopaminergic neurons and patient-derived fibroblasts (7, 8, 41, (43) (44) (45) (46) , have disclosed a role for ATP13A2 in the positive modulation of autophagy and lysosomal functionality (i.e. acidification and degradation capacity) (7, 8, 14, 18, 26, 27, 41, (43) (44) (45) (46) . A recent study, moreover, has shown that synaptotagmin 11, a PD-linked gene with functions in vesicular fusion, trafficking and exocytosis, is regulated by ATP13A2 at the transcriptional (via TFEB) and post-translational levels (through ubiquitination) (26) . Our study, however, suggests that under proteotoxic stress conditions ATP13A2-mediated removal of Ub-proteins occurs through mechanisms that are mainly unrelated to autophagic degradation of these substrates. The reason underlying the discrepancy between previous work, showing that under baseline or starvation conditions ATP13A2 OE improves and KD compromises autophagic degradation and lysosomal function (11, 21, 26, 27) , and our findings, this is not completely clear. However, it should be noted that this is the first report highlighting a role for ATP13A2 in melanoma cells evoked by the inhibition of the ubiquitin proteasome system. It is possible that inhibition of the ubiquitin proteasome system may alter the availability of putative ATP13A2 interactors (20) , among which there are several chaperones known to be expressed at high levels in melanoma and other cancer cells (5, (47) (48) (49) , ultimately modulating its function. These are interesting possibilities that deserve further studies.
We previously reported that the combined binding of PA and PI(3,5)P2 to the ATP13A2 N-terminus unlocks ATP13A2 activity providing cellular protection towards mitochondrial-mediated (19) and metal-induced toxicity (13, 19, 50) . Here, we show, using both pharmacological and genetic approaches, that the ATP13A2 N-terminal scaffold function also requires PI(3,5)P2 binding, since inhibition of PIKfyve (the sole enzyme producing PI(3,5)P2) interferes with the enhanced Ub-proteins turnover of the ATP13A2-overexpressing cells. In contrast, chemical inhibition of PLD, by FIPI, has no impact on the Ub-proteins phenotype. Interestingly, blockage of PLD-mediated PA production has been shown to prevent ATP13A2-mediated protection against mitochondrial ROS or metal toxicity, a phenotype that depends on the transport activity of ATP13A2 (19) . These findings combined suggest that mainly the interaction of PA to the ATP13A2 N-terminus controls the activation of ATP13A2 transport, while PI(3,5)P2 facilitates both ATP13A2's scaffold and transport properties. This highlights that ATP13A2's function is heavily regulated by the type of cellular stress and that the Nterminus exerts a dual function, as lipid-mediated activity switch and scaffold. Since the transport function of ATP13A2 is currently unknown, it remains unclear whether these two functionalities are mechanistically coupled. Besides the site for lipid interactions, the relatively long ATP13A2 N-terminus might also be an acceptor domain for regulatory proteins, since over forty protein interactors were previously identified by a splitubiquitin yeast two hybrid approaches. Several of those are implicated in the endo-/lysosomal system regulating vesicular trafficking (20, 21) . Thus, it is possible that these interacting proteins bind to the N-terminus regulating the scaffolding and/or transport modalities of ATP13A2, in a cellular stress-modulated manner.
Here, we show that upon binding of PI (3, 5) P2 to the N-terminus, ATP13A2 facilitates Ub-proteins cargo sorting and export through nanovesicles. This finding is highly relevant since PI (3, 5) P2 is an endosomal membrane lipid with essential roles in the regulation of lysosomal function and signalling. PI(3,5)P2 has been found to regulate lysosomal motility, tubulation and reformation, due to the interaction with dynein motors (51) , and to modulate actin turnover at the level of the late endosomes, by binding to cortactin (52) . Moreover, sorting of Ub-cargo into the MVBs for export through exosomes, is also associated with the ESCRT complexes ability to bind to PI(3,5)P2 (53) . Interestingly, PI(3,5)P2 has been shown to be a positive regulator of mTORC1 functions in yeast. PI (3, 5) P2 promotes nutrientregulated endocytosis and inhibits autophagy by modulating mTORC1-dependent phosphorylation of Npr1 and Atg13, respectively (54, 55) , mechanism likely to be conserved in mammalian cells. Thus, it is possible that conditions altering the cellular availability or compartmentalization of PI(3,5)P2 modulate the (scaffolding) functions of ATP13A2 within the endo-/ lysosomal network and on the autophagy machinery. This hypothesis urges further mechanistic studies.
Here, we show that the ATP13A2-mediated secretion of nanovesicles can be fully recapitulated by an inactive N-term fragment of ATP13A2. Since ATP13A2 has been shown to promote the secretion of alpha-synuclein within nanovesicles, such as exosomes (12) in neurons (13) , it is possible that the N-terminal fragment of ATP13A2 might have the general function of "sensing" dysfunctional accumulation of Ub-conjugated proteins, such as in cells undergoing proteotoxic stress, and favour their exodus through the endo-/lysosomal pathway. Future studies will be required to determine whether the loss of function character of ATP13A2 disease mutations in various pathological conditions is related to a loss of transport and/or scaffolding functions. Although the biological consequences of this ATP13A2 regulated switch require further studies, our findings reveal a novel and potentially druggable function of the N-terminal fragment of ATP1312, in the regulation of trafficking, sorting and ultimately export of intracellular cargo, to the extracellular environment. non-essential amino acids, 0.1% Gentamicin (Sigma-Aldrich, G7513, M7145, G1264, respectively) as well as 15% fetal bovine serum (FBS) (GE healthcare, Healthcare systems, Diegem, Belgium) for SHSY5Y but 1% Glutamine, 1% penicillin/streptomycin (Sigma-Aldrich, P0781) and 10% FBS for A375p. Fibroblasts derived from healthy donors or Hereditary Spastic Paraplegia (HSP)-patients carrying ATP13A2 mutations (T512I) (7) or the Kufor-Rakeb patients with truncating p.Phe851Cysfs*6 mutation (p.F851CfsX856), causing a premature stop codon (56), were cultured in BME (Basal Medium Eagle) (Thermo Scientific, 21010046) containing 1% Glutamine, 1% penicillin/streptomycin (Sigma-Aldrich, P0781) and 10% FBS. All cell lines were maintained in the incubator at 37 C and 5% CO 2 for a maximum of 10 passages and regularly checked for mycoplasma contamination.
Materials and Methods
Materials
DNA constructs of ATP13A2
SHSY5Y neuroblastoma and A375p melanoma cell lines stably expressing firefly luciferase (control), WT ATP13A2, D508N ATP13A2, flag-N-MA-M1 and the mutant on the putative Nterminal Lipid Binding Site (LBS123:65FRWKP!FAWAP;74RLRLR !ALALA; 155KRVLR!AAVLA) or sh-ATP13A2 (KD) (10, 19) were generated via lentiviral transduction and maintained as described previously (10) .
Transient transfection
ATP13A2 modulated cell lines were transiently transfected (1 mg: 3 ml; ratio of DNA/lipofectamine) with either GFP-Ub, GFP-LC3 or RFP-GFP-LC3, GFP-N-MA-M1 (detailed in (10)) using lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA, 12566014) reagent and diluted in 100 ml FBS-free medium. Following 15 min incubation in room temperature, the diluted DNA were pipetted into the medium of seeded cells (1Â 10 5 cells per well). Then, cells were kept for few hours in serum freetransfection media and then 1 ml full medium was added, and the cells were further incubated overnight at 37C . By the next day, they were refreshed with full medium and used the following day for treatment.
Measurement of autophagic flux
ATP13A2 modulated cell lines were transiently transfected with tandem fluorescent-tagged LC3 (mRFP-EGFP-LC3) construct (57), and autophagic flux was monitored by fluorescent imaging as described previously (58) . Additionally, autophagic flux was assessed in all cell lines by pre-treatment for 1 h with Bafilomycin A1 (10nM, dissolved in DMSO) (59).
Drug treatment
All experiments were performed in standard culture media without the addition of selective antibiotics. To inhibit the proteasome, A375p and SHSY5Y cell lines were treated with either Bortezomib (Borte dissolved in PBS at the concentrations of 10 nM in SHSY5Y cells, 100 nM in A375p cells and 1 mM in patient derived fibroblasts) or MG132 (10 mM, dissolved in DMSO). To inhibit the formation of the lipid PI(3,5)P2, cells were pre-treated for either 3 h (SHSY5Y) or 1 h (A375p) with the PIKfyve kinase inhibitor YM-201636 (PIKfyve, 400 nM and 200 nM respectively, dissolved in DMSO) (10). 
Preparation of cell extracts
Isolation of protein aggregates
After treatment, cells were resuspended in a lysis RIPA buffer and centrifuged at 800 g for 5 min. After centrifugation, the supernatant was designated as the "cytoplasmic fraction" and the pellet was resuspended in the same lysis buffer containing an additional 1% SDS (w/v). The cell suspension was sonicated at high intensity for 4 ON-OFF intervals of 10s each. The suspension was incubated for 15 min at RT with gentle shaking. Supernatant was recovered after centrifugation at 20000 x g for 30 min at RT and indicated as the "aggregate fraction". Protein concentration of either fraction was determined using the BCA assay.
Western blot
To assess protein expression 50 mg of protein were separated using SDS-PAGE. Afterwards, proteins were transferred electrophoretically onto the nitrocellulose Membranes (GE healthcare, Healthcare systems, Diegem, Belgium) and subsequently blocked with 5% non-fat milk in TBS-Tween (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 1 h prior to the addition of an array of primary antibodies and further incubated overnight 4 C.
Primary antibodies were labelled by the relevant secondary antibodies, including anti-rabbit-DyLight 800 and anti-mouseDyLight 680 (Thermo Scientific, Waltham, MA, USA, 35571 and 35519) at a 1:2000 dilution. Images were taken and quantified using an Odyssey infrared imaging device (Li-Cor Biosciences, Lincoln, NE, USA) and analysed by ImageJ 1.49v and Graph Pad Prism 6.
Immunostaining
ATP13A2 cell lines were plated at a density of 1Â10 5 cells per well and cultured on cover slides in 6 well-plates. Cells were then treated overnight. At the relevant time points, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, Bornem, Belgium) at 37 C for 20 min. Cellular permeabilization was induced with 0.1% Triton X-100 (Sigma-Aldrich, Bornem, Belgium) for 10 min at room temperature. Afterwards, coverslips were blocked in PBS containing 1% BSA (Sigma-Aldrich, Bornem, Belgium) and 10% FBS for 1h at room temperature, followed by the incubation with primary antibodies; ATP13A2 and LAMP1 (ab25630, Abcam) or CD63 (11-343-C100, Exbio), diluted in blocking solution at 4 C overnight. Samples were then washed twice with PBS, and stained coverslips were labelled with Alexa Flour 488-or Alexa Flour 546-conjugated secondary antibodies for 1 h in RT. Nuclei were also counterstained with DAPI (1 lg/Ml) (Sigma-Aldrich, Bornem, Belgium), mounted using Prolong Gold anti-fade reagent and cured overnight. Confocal images were captured using confocal microscopy ZEISS Axiovert 100M LM510 and Zeiss plan-Apochromat 63Â: 1.4 NA oil immersion objective and/or Nikon A1R EcliApse Ti with Apo 60X (1,40 oil) objective.
In some experiments, A375 cell lines expressing ATP13A2 were transiently transfected with GFP-Ub/GFP-LC3/mRFP-GFP-LC3, and cultured on cover slides. After 48 h, cells were subjected to Borte 100 nM and further incubated for the desired time. Immunostaining was performed as described above, if requested. Finally, cells were visualized using confocal microscopy (ELISS Axiovert 100M LM10 and/or Nikon A1R Eclipse Ti with Apo 60X (1, 40 oil) objective).
Nanovesicle isolation
To isolate nanovesicles, cell lines were cultured with an initial equivalent cell number (4 Â 10 6 cells/plate for SHSY5Y and 3Â10 6 cells/plate for A375p). Upon reaching semi-confluence, cells were washed two times with PBS and refreshed with DMEM consisting of 1% exosome-depleted FBS with defined treatments. 24 h later, the cell-conditioned media was collected and pulled from triplicate cultures. Nanovesicles were purified using a differential centrifugation method at 4 C: 15 min at 500 Â g to remove cells; 30 min at 10,000 to eliminate cell debris; filtration of apoptotic bodies with 0.22 lm filter (Merck Millipore, Darmstadt, Germany) and final centrifugation at 140,000 Â g for 3 h to pellet nanovesicles. Supernatant was decanted and nanovesicles collected in 50 ml RIPA buffer. Then, protein concentration of the fractionated vesicles are determined by commercially available BCA Protein Assay Kit (23223, Thermo Scientific, Waltham, MA, USA, 23228, followed by manufacturer's instructions) and 50 mg of the protein is loaded on the gel.
Statistical analysis
Data were presented at the average 6 SEM, of at least three independent experiments. Statistical analysis was conducted using Graph Pad Prism 6 by 2-way ANOVA with a Bonferroni post hoc test or Tukey Test when appropriate. Considered significance */$ P < 0.05, **/$$ P < 0.01, ***/$$$ P < 0.001 and ****/ $$$$ P < 0.0001. Computer package of ImageJ 1.49v was used for densitometry analysis of immunoblot signals and mean fluorescence intensity/puncta analysis of images.
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